Autoantibodies Targeting AT1- and ETAR-Receptors Link Endothelial Proliferation and Coagulation via Ets-1 Transcription Factor

Rusan Catar 1,2,*, Melanie Herse-Naether 1,2, Nan Zhu 1,3,©, Philine Wagner 1,2, Oskar Wischnewski 1,2, Angelika Kusch 1,2,4, Julian Kambhire-Milz 5, Andreas Eisenreich 6, Ursula Rauch 6, Björn Hegner 1,2,7, Harald Heidecke 8, Angela Kill 9,10, Gabriela Riemekasten 9,10,11, Gunnar Kleinau 12, Patrick Scheerer 12,13,©, Duska Dragun 1,2,4,© and Aurelie Philippe 1,2,4,©

1 Department of Nephrology and Medical Intensive Care, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; melanie.naether@gmail.com (M.H.-N.); znnance@yeah.net (N.Z.); Philine.wagner@yahoo.com (P.W.); oskar.wischnewski@charite.de (O.W.); angelika.kusch@charite.de (A.K.); bjorn.hegner@gmx.de (B.H.)
2 Center for Cardiovascular Research, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
3 Shanghai General Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
4 Berlin Institute of Health, Charité—Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, 10117 Berlin, Germany
5 Department of Transfusion Medicine, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; julian.milz@charite.de
6 Department of Cardiology, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; andreas.eisenreich@gmx.de (A.E.); urasula.rauch@charite.de (U.R.)
7 Vitanas Klinik für Geriatrie, 13435 Berlin, Germany
8 CellTrend GmbH, 14943 Luckenwalde, Germany; heidecke@celltrend.de
9 Deutsches Rheuma-Forschungszentrum (DZR), A. Leibniz Institute, 10117 Berlin, Germany; Angela.Kill@web.de (A.K.); gabriela.riemekasten@uksh.de (G.R.)
10 Department of Rheumatology and Clinical Immunology, CCM, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany
11 Priority Area Asthma & Allergy, Research Center Borstel, Airway Research Center North (ARCN), Members of the German Center for Lung Research (DZL), 23845 Borstel, Germany
12 Group Protein X-ray Crystallography and Signal Transduction, Institute of Medical Physics and Biophysics, Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany; gunnar.kleinau@charite.de (G.K.); patrick.scheerer@charite.de (P.S.)
13 DZHK (Deutsches Zentrum für Herz-Kreislauf Forschung), Partner Site Berlin, 13353 Berlin, Germany
* Correspondence: rusan.catar@charite.de (R.C.); aurelie.philippe@bih-charite.de (A.P.);
Tel.: +49-30-5055-9248 (R.C.); +49-30-5055-9318 (A.P.)
† Deceased on 28 December 2020.

Abstract: Scleroderma renal crisis (SRC) is an acute life-threatening manifestation of systemic sclerosis (SSc) caused by obliterator vasculopathy and thrombotic microangiopathy. Evidence suggests a pathogenic role of immunoglobulin G (IgG) targeting G-protein coupled receptors (GPCR). We therefore dissected SRC-associated vascular obliteration and investigated the specific effects of patient-derived IgG directed against angiotensin II type 1 (AT1R) and endothelin-1 type A receptors (ETAR) on downstream signaling events and endothelial cell proliferation. SRC-IgG triggered endothelial cell proliferation via activation of the mitogen-activated protein kinase (MAPK) pathway and subsequent activation of the E26 transformation-specific-1 transcription factor (Ets-1). Either AT1R or ETAR receptor inhibitors/shRNA abrogated endothelial proliferation, confirming receptor activation and Ets-1 signaling involvement. Binding of Ets-1 to the tissue factor (TF) promoter exclusively induced TF. In addition, TF inhibition prevented endothelial cell proliferation. Thus, our data revealed a thus far unknown link between SRC-IgG-induced intracellular signaling, endothelial cell proliferation and active coagulation in the context of obliterator vasculopathy and SRC. Patients’ autoantibodies and...
their molecular effectors represent new therapeutic targets to address severe vascular complications in SSc.

**Keywords:** angiotensin; renin–angiotensin system; endothelin-1; systemic sclerosis; renal crisis; autoantibodies; coagulation

1. Introduction

Systemic sclerosis (SSc) is an autoimmune disease which affects multiple organs, with a wide range of clinical manifestations. Scleroderma renal crisis (SRC), a rare and critical manifestation of SSc, highly affects morbidity and mortality, especially when refractory to treatment [1]. One of its key features, obliterative vasculopathy, is initiated by vascular remodeling in the interlobar arteries [2], although activation of the coagulation cascade has also been shown to be involved in the pathology [3]. In addition, inhibition of the renin–angiotensin system has dramatically improved the therapy of SRC, although the underlying molecular mechanisms are not well understood [4].

Interestingly, autoantibodies targeting AT$_1$R are involved in the occurrence of obliterative vasculopathy in preeclampsia [5], as well as in kidney and heart transplant rejection [6–8]. In 2011, their role in the pathophysiology of SSc, as well as their association with renal crisis and increased mortality risk, were identified [9]. Concomitantly, autoantibodies targeting ET$_A$R were detected in SSc patients and presented the same features as AT$_1$R-IgG. In transplant pathologies, an association with ET$_A$R-IgG is already well established [7,10].

In addition, a previous study using receptor-specific IgG isolated from kidney transplant recipients with vascular pathology showed that AT$_1$R stimulates TF activation in an acute clinical setting [6]. Passive transfer of patient’s IgG to rats with kidney grafts induced renal lesions [6].

We hypothesized that the endogenous ligands of AT$_1$- and ET$_A$ receptors activate different intracellular signaling pathways compared to pathological SRC-IgG complexes. The known ability of GPCRs to respond to different agonists such as endogenous ligands, or even antibodies by triggering specific activation of different downstream signaling pathways [11], supports this assumption.

The aim of the current study was therefore to investigate in detail the signaling pathways that are specifically activated by IgG from SRC patients. We demonstrate that SRC-IgG affected the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) signaling cascade. Moreover, we examined the cellular phenotype triggered by this specific activation to decipher its underlying mechanisms. Our present study provides new insights into the pathogenetic molecular mechanisms of obliterative vasculopathy in SRC and the involvement of AT$_1$R and ET$_A$R-IgG.

2. Results

2.1. Autoantibodies against AT$_1$R/ET$_A$R Activate Ets-1 Transcription Factor via the ERK1/2 Pathway

We first verified whether ERK1/2 activation in HMEC-1 occurs upon stimulation with SRC-IgG [9]. IgG prepared from SRC patients carrying AT$_1$R-/ET$_A$R-autoantibodies (IgG levels > 10 U/mL in ELISA) strongly increased ERK1/2 phosphorylation (Figure 1a). This effect was less pronounced with either endogenous ligands AT-II and ET-1 (0.8 and 1.65, respectively, vs. 4.05 with IgG), or IgG from healthy controls (Ctrl-IgG) (Figure 1a).

In agreement with previous results [9], the inhibition of MEK-1 (a kinase upstream from ERK1/2) with the specific inhibitor PD 184,352 abolished ERK1/2 activation by both AT-II and ET-1, as well as by SRC-IgG (Figure 1a). In summary, these assays confirm that ERK1/2 activation in endothelial cells occurs directly after stimulation with SRC-IgG.
Notably, it has been reported that healthy individuals do carry AT1R- and ETAR-IgG [12]. We demonstrated that although such healthy donor IgG do activate ERK1/2 (Figure 1a), such activation does not involve either AT1R or ETAR signaling (Figure S1, absence of the effect of AT1R and ETAR inhibitors on Erk phosphorylation), in contrast to SRC-IgG.

To determine the intracellular mechanisms underlying ERK1/2 immune activation, we focused further downstream on Ets-1, a transcriptional regulator in AT-II- and ET-1-mediated effects [13–16], and on the causative TF in autoimmune chronic pathologies [17,18]. Time-dependent HMEC-1 stimulation with SRC-IgG showed a maximal increase in Ets-1 transcript (Figure 1b left) and protein expression (Figure 1b right) one hour after the start of the stimulation, persisting over 12 h in contrast to Ctrl-IgG. Transcriptional SRC-IgG effects were comparable to the effects generated by the stimulation of HMEC-1 with AT-II and ET-1 (Figure S2).

Next, we explored Ets-1 expression caused by SRC autoantibody stimulation by treating endothelial cells with the AT1R- or ETAR inhibitors Valsartan and Sitaxentan, respectively. Such treatment abolished the increase in Ets-1 at transcriptional level down to 14% with Sitaxentan, and down to 28% with Valsartan (Figure 1c). It is known that ERK1/2 mediates Ets-1 transcriptional activity by phosphorylating threonine 38 (Thr38) of the Ets-1 protein [19]: AT1R and ETAR inhibitors specifically decreased such Ets-1 phosphorylation to 14% with Sitaxentan, and down to 28% with Valsartan (Figure 1c). It is known that ERK1/2 mediates Ets-1 transcriptional activity by phosphorylating threonine 38 (Thr38) of the Ets-1 protein [19]: AT1R and ETAR inhibitors specifically decreased such Ets-1 phosphorylation.
An absence of the effects of AT$_2$R and ET$_B$R inhibitors or Ctrl-IgG is shown for comparison. These results demonstrate that SRC-IgG activates ERK1/2-signaling, thereby increasing Ets-1 signaling activity via AT$_1$R and ET$_A$R.

2.2. AT$_1$R/ET$_A$R Autoantibodies Trigger Endothelial Cell Proliferation via an ERK1/2—Ets-1 Signaling Pathway

Endogenous ligands induce endothelial cell proliferation via AT$_1$R and ET$_A$R in endothelial cell types such as human umbilical endothelial vein cells (HUVECs) [20–22]; therefore, we next investigated whether SRC-IgG could trigger similar responses in endothelial cells.

BrdU incorporation revealed that 24 h of stimulation with SRC-IgG indeed increased HMEC-1 proliferation (Figure 2a left and right), although endogenous ligands and Ctrl-IgG failed to impact endothelial cell proliferation. Furthermore, pre-incubation with AT$_1$- and ET$_A$R inhibitors abolished such SRC-IgG-induced proliferative responses, and even decreased it under the control level for Sitaxsentan (Figure 2a left and right, respectively), suggesting a receptor-specific proliferative effect of SRC-IgG. Additionally, inhibition of the upstream regulators of ERK1/2 signaling, cRaf1 and MEK-1, prevented this observed proliferation boost (Figures 2b and S3), demonstrating a direct link between activating antibody-mediated stimulation of the ERK1/2 pathway and endothelial cell proliferation in HMEC-1.

It has previously been reported that Ets-1 acts as a negative regulator of endothelial apoptosis during embryogenesis [23]. Therefore, we used shRNA to knock down Ets-1 expression in HMEC-1 before exposing it to healthy or patient IgG. Western blots revealed that shRNA prevented Ets-1 protein level increases in cells stimulated with SRC-IgG but did not change the Ets-1 protein expression in cells exposed to Ctrl-IgG (Figure 2c). This indicates an induction of Ets-1 synthesis in response to SRC-IgG but not Ctrl-IgG. Moreover, shRNA targeting Ets-1 reduced endothelial cell proliferation in cells treated with SRC-IgG but had no effect on cells that received Ctrl-IgG (Figure 2d).

We conclude that the SRC-IgG-mediated stimulation of AT$_1$R/ET$_A$R activates ERK1/2, and that its downstream signaling induces the Ets-1 transcription factor which, in turn, promotes endothelial cell proliferation.

2.3. Tissue Factor Expression Is Positively Regulated by Ets-1 Binding in the Promoter Region

To complete this cascade of Ets-1 regulated mechanisms with effector proteins, we considered TF as a biologically important and potential downstream effector target due to its demonstrated crucial role in the coagulation cascade [24,25]. To establish a direct link between Ets-1 and TF regulation in SRC-related vascular obliteration, we performed promoter analysis of the TF gene using dual luciferase assays. TF promoter deletion constructs showed that a motif located within 495 base pairs downstream of TF transcription initiation site is essential for TF expression induced by both endogenous ligands (Figure 3a left) and SRC-IgG (Figure 3a right). AT$_1$R- and ET$_A$R-inhibitors abolished all increases in promoter activity, again demonstrating specificity to these receptors (Figure 3b, left and right).

The luciferase assays were expanded to the endogenous TF promoter. Hence, we first assessed the presence of an active Ets-1 binding site in the promoter. An EMSA (electrophoretic mobility shift assay) showed specific binding of Ets-1 to the TF promoter, which was even higher upon SRC-IgG stimulation. This binding was lost upon the addition of specific non-labeled DNA. Moreover, addition of the Ets-1 antibody confirmed that the DNA fragment was occupied by Ets-1 (Figure 3c). We performed chromatin immunoprecipitation (ChIP) with anti-Ets-1 antibodies on stimulated HMEC-1 (Figure 3d left (Ets-1 binding site flanking primers) and right (binding site-independent primers, negative control)) and confirmed our promoter analyses conclusions (Figure 3a); immunoprecipitation with Ets-1 antibodies specifically yielded a Ets-1 binding site PCR product of expected size, enriched upon ligand or activating IgG stimulation.
TF expression in HMEC-1 in response to SRC-IgG.

To establish a direct link between Ets-1 and TF regulation in SRC-related vascular obliteration, we performed immunoprecipitation (ChIP) with anti-Ets-1 antibodies on stimulated HMEC-1. Figure 3a shows that a motif located within 495 base pairs downstream of TF transcription initiation site is essential for TF expression induced by both endogenous ligands (Figure 3a, left) and SRC-IgG (Figure 3a, right). AT1R- and ETAR-inhibitors abolished all increases in TF promoter activity, again demonstrating specificity to these receptors (Figure 3b, left and right).

We further tested whether increasing TF expression modulated its activity. AT-II and ET-1 stimulation indeed increased TF activity (46% and 87% increases in comparison to control, Figure 4b). Ctrl-IgG had minimal effects. A potential comparable to ET-1 (79% increase compared to control, Figure 4b). Ctrl-IgG again confirmed by the lack of increase in TF activity upon pre-treatment with AT1R/ETAR inhibitors (Figure 4b). Similarly, Ets-1 knockdown in HMEC-1 demonstrated the essential role of Ets-1 for TF activity induced by SRC-IgG, whereas Ets-1 was not involved with

**Figure 2.** Endothelial cell proliferation elicited by SRC-IgG via ERK1/2–Ets-1 signaling. Non-stimulated cells (Ctrl) were used as reference when natural ligands were included, whereas Ctrl-IgG served as reference when only IgG were used. HMEC-1 were stimulated for 24 h with either natural ligands, Ctrl- or SRC-IgG, and specificity was assessed via two-hour pre-incubation with corresponding receptor inhibitors (a (left and right) or cRaf1 inhibitor (b). (c) Abolition of Ets-1 translational regulation by shRNA following six-hour HMEC-1 stimulation. Ctrl shRNA corresponds to a mix of three control shRNA plasmids. Blots were over-exposed to better appreciate the decrease in the protein level. (d) Decrease in SRC-IgG induced endothelial cell proliferation by Ets-1 knockdown. (a–c) n = 4, (d) 7 ≤ n ≤ 11; representative blots are shown. * p < 0.05.

Taken together, these findings demonstrate that an active Ets-1 binding site exists in the TF promoter, >495 base pair upstream of transcription initiation site, which stimulates TF expression in HMEC-1 in response to SRC-IgG.

### 2.4. SRC-IgG-Mediated Ets-1 Signaling Induces TF-Dependent Proliferation

After confirming that AT1R/ETAR stimulation increased Ets-1 binding to the TF promoter (Figure 3), we further investigated the effect on TF mRNA in HMEC-1. Transcriptional levels of TF transiently tripled one hour following SRC-IgG (but not Ctrl-IgG stimulation; Figure 4a left), which, in turn, became considerably upregulated TF protein levels after six hours of stimulation (Figure 4a right, endogenous ligands and Ctrl-IgG had minimal effects).

We further tested whether increasing TF expression modulated its activity. AT-II and ET-1 stimulation indeed increased TF activity (46% and 87% increases in comparison to the control, respectively, Figure 4b) [26], whereas stimulation with activating IgG exhibited a potential comparable to ET-1 (79% increase compared to control, Figure 4b). Ctrl-IgG had an effect in the range of what was observed with AT-II. The receptor specificity was again confirmed by the lack of increase in TF activity upon pre-treatment with AT1R/ETAR inhibitors (Figure 4b). Similarly, Ets-1 knockdown in HMEC-1 demonstrated the essential role of Ets-1 for TF activity induced by SRC-IgG, whereas Ets-1 was not involved with
Ctrl-IgG (Figure 4c). This was corroborated by supplemental data, where SRC-IgG, but not Ctrl-IgG, stimulated thrombin protein release in HMEC-1 (Figure S4).

Taken together, these findings demonstrate that an active Ets-1 binding site exists in the TF promoter, >495 base pair upstream of transcription initiation site, which stimulates TF expression in HMEC-1 in response to SRC-IgG.

Figure 3. Ets-1 binding to the TF promoter upon AT1R/ETAR stimulation by either respective natural peptide ligand or in response to SRC-IgG. (a) (left and right) Dual luciferase assay shows a TF promoter activity increase in response to either receptor-activating scenarios as compared with non-stimulated or Ctrl-IgG treated cells. (b) (left and right) Observed activation is abolished by specific AT1R or ETAR inhibitors. (c) EMSA performed with nucleus proteins of endothelial cells incubated with TF promoter DNA. Shift specificity was assessed using non-labeled DNA, the incubation with Ets-1-specific antibodies triggering a supershift. (d) (left and right) Chromatin immunoprecipitation (ChIP) performed using stimulated cells, the DNA of which was precipitated with an antibody directed against Ets-1. (a) left, (b,d) n = 4, (a) right, (c) n = 3; representative blots are shown. *p < 0.05.

Finally, we investigated the link between TF and endothelial cell proliferation. For this purpose, HMEC-1 were pre-incubated with specific TF-inhibiting antibodies before stimulation with Ctrl- or SRC-IgG. TF-inhibiting antibodies specifically and significantly reduced SRC-IgG-induced endothelial cell proliferation (39% decrease), whereas they only had a limited effect upon stimulation with Ctrl-IgG (15% decrease) (Figure 4d).

These results clearly demonstrate that TF acts as a downstream effector of Ets-1 in the ERK 1/2 immune-induced signaling pathway mediating endothelial cell proliferation in SRC (Figure 5).
Representative blots are shown. * Specific inhibition of AT1R/ETAR abolishes TF activity increase. (c) Ets-1 knockdown abolishes TF protein synthesis. (d) BrdU incorporation shows that pre-incubation with a TF-blocking antibody annihilates endothelial cell proliferation elicited by SRC-IgG. (a, c) n = 4, (d), 4 ≤ n ≤ 7; representative blots are shown. * p < 0.05, ** p < 0.01.

Figure 4. TF involvement in endothelial cell proliferation. Non-stimulated cells (Ctrl) were used as a reference when natural ligands were included, whereas Ctrl-IgG served as a reference when only IgG were used. (a) Transcriptional (left) and translational analysis (right) of TF after endothelial cell stimulation. (b) Specific inhibition of AT1R/ETAR abolishes TF activity increase. (c) Ets-1 knockdown abolishes TF protein synthesis. (d) BrdU incorporation shows that pre-incubation with a TF-blocking antibody annihilates endothelial cell proliferation elicited by SRC-IgG. (a, c) n = 4, (d), 4 ≤ n ≤ 7; representative blots are shown. * p < 0.05, ** p < 0.01.

Figure 5. Proposed intracellular cascade following AT1R and ETAR activation by SRC-IgG. Binding of SRC-IgG to the receptors triggers the activation of cRaf1, MEK, ERK1/2 and, in turn, of Ets-1, through phosphorylation of its Thr38. Once activated, Ets-1 binds to the promoter of TF, triggering its expression (mRNA and protein). This intracellular pathway results in endothelial cell proliferation, inducing obliterative vasculopathy in SSc patients.
3. Discussion

Our study provides evidence that activating autoantibodies directed against AT$_1$R/ET$_A$R trigger a specific signaling pathway linking the transcriptional control of endothelial cell proliferation with increased pro-coagulatory properties in scleroderma renal crisis (SRC). Exposure of microvascular endothelial cells to receptor-activating antibodies triggered ERK1/2 phosphorylation, increased further downstream Ets-1 transcription factor activation and led to subsequent synthesis of TF as Ets-1 target gene and initiator of coagulation. This cascade was not observed upon activation with the natural ligands of the receptors. With this newly described molecular mechanism, we expand our previous findings [9] and offer potential explanations as to why SRC patients harboring AT$_1$R- and ET$_A$R-IgG present an increased risk for the earlier occurrence of severe and potentially lethal vascular complications in the kidney.

In this study, we concentrated on SRC-IgG and their involvement in the pathogenesis of SRC. Antibodies other than AT$_1$R- and ET$_A$R-IgG have been associated with SRC. Anti-RNA polymerase III antibodies (ARA), especially, have been associated with kidney manifestations of systemic sclerosis [27–29]. However, although these antibodies constitute a biomarker of SRC, no studies show that these antibodies participate actively in the occurrence of the disease. In the publication from Mouthon L. et al., three out of the four SRC patients tested presented anti-Topoisomerase I antibodies (ATA) [27]; according to the literature, antinuclear antibodies, among which include ARA and ATA, are mutually exclusive [30]. Moreover, ATA is associated with the occurrence of interstitial lung disease, but not with SRC [31].

Our work presents the involvement of the ERK1/2–Ets-1 signaling pathway in the occurrence of SRC vascular lesions. Members of the ETS transcription factor family participate in the regulation of inflammatory and angiogenic responses in endothelial cells [19]. The Ets-1 protein structure contains a conserved DNA-binding domain, forming a winged helix-turn-helix structure. Other Ets-1 target genes, such as the IL-8 gene, can be induced by SRC-IgG stimulation, as we have previously demonstrated [32]. Ets-1 activation is also involved in chronic autoimmune pathologies such as rheumatoid arthritis [18] and lupus [17].

Several reports indicate a role of Ets-1 in endothelial cell proliferation [33,34]. In a pathological paradigm of murine carotid–jugular fistula, Ets-1 expression has been shown to be increased in the neointima and overlying endothelium [35]. In terms of signaling, chronic infusion of AT-II in mice induces Ets-1 expression in endothelial cells [16]. Our results imply that SRC-IgG cause endothelial proliferation through Ets-1-mediated transcriptional program, notably its subsequent chronic activation of TF. TFs act as the primary initiator of the in vivo coagulation cascade. The endothelium itself has been shown as an important source of TF [36]. Uncontrolled endothelial proliferation, combined with increased pro-coagulatory properties of the endothelium of middle-sized arteries and arterioles, can contribute to the formation of onion-skinning concentric narrowing, which then leads to the obliteratorive vasculopathy observed in kidneys during SSc [37]. Studies of antiphospholipid syndrome have demonstrated that autoantibodies can exert an influence on TF expression on either monocytes [38] or endothelial cells [39].

Notably, the differences observed between the proliferation measures in Figure 3a,b,d are most likely due to the use of distinct experimental methods (namely, a Roche proliferation kit for the 3a/b and BrdU immunofluorescence for 3d), not actual biological difference. Activation of the ERK–Ets-1–TF axis was investigated here in human endothelial cells. However, AT$_1$R and ET$_A$R are also strongly expressed in renal vascular smooth muscle cells, (vSMCs) [40,41]. Moreover, SRC has been associated with the proliferation of both endothelial and vascular smooth muscle cells [42]. Hence, we cannot exclude that the signaling pathway we describe also occurs in vSMCs, and further studies are needed to clarify whether these cells are also affected by SRC-IgG. One such modern approach to identify how SRC-IgG differentially influence EC and vSMC would be single-cell sequencing. Two recent articles have thus investigated the relative impact of EC and vSMC in
hypertension-induced vascular remodeling [43,44]. In a mouse model of salt-induced hypertension, Zhang et al. showed that hypertensive vessels present increased smooth muscle cell populations, partly due to endothelial-to-mesenchymal cell transition [44]. In a context of systemic sclerosis, single-cell sequencing was used to study immune cell heterogeneity between patients and healthy controls using skin samples [45], or whole endothelial cell genetic patterns in individuals with or without the disease [46]. Such investigations would be of particular interest in blood vessels from SRC patients to identify the consequences of SRC-IgG on specific cell types. Obviously, a single-cell sequencing approach in blood vessel would require spatial cell type identification, one of which possibilities could be to couple this method with spatial transcriptomics, as the group of H. Benjamin published recently for acute kidney injury [47].

We observed differences between the actions mediated by SRC-IgG and natural ligands. In HMEC-1, patient IgG and ET-1 activated ERK 1/2 and Ets-1, although ET-1-driven activation was significantly lower in comparison with SRC-IgG. In the literature, the ET-1 activation of ERK 1/2–Ets-1 signaling has exclusively been reported once in human peritoneal mesothelial cells [33]. In contrast, AT-II has been reported three times as an Ets-1 activator, but exclusively in renal or cardiac fibroblasts [48–50].

In addition, in contrast to SRC-IgG, neither AT-II nor ET-1 increased HMEC-1 proliferation. AT-II has, however, recently been associated with increased proliferation in lymphatic endothelial cells, and previously in human umbilical vein endothelial cells (HUVECs) [20,51]. AT1R stimulation triggered angiogenesis in both instances, a mechanism not involved in the present work. Additionally, three reports demonstrated that ET-1 increases endothelial cell proliferation [52–54], although in each case, the ETA receptor inhibitor was only mildly efficient, whereas the ETB receptor blocked the observed effects.

Finally, TF protein expression was only moderately increased in response to either natural ligand (in contrast to SRC-IgG), which was mirrored by a moderate induction of TF activity compared with SRC-IgG. AT-II-induced increases in TF expression had already been reported in monocytes [55] and transgenic rats showing cardiac vasculopathy [56]. ET-1 links to TF are less well documented, but have been shown in children with bronchopulmonary dysplasia [57], whereas the induction of TF by AT1R-IgG has already been reported in women with preeclampsia and in acute kidney graft rejection by our group [6,58]. In the present study, TF activation by SRC-IgG was mediated by Ets-1. On the other hand, our previous sister reports in preeclampsia and kidney graft rejection involved AP-1 and/or NF-κB [6,58]. Articles establishing TF activation by AT-II also involved NF-κB [55,56]. Hence, although the massively decreased TF expression following Ets-1 inhibition makes such a hypothesis unlikely, further studies are needed to establish whether AP-1 and NF-κB also participate in SRC and TF induction.

According to the data presented here, AT1R inhibitors should prove beneficial in the treatment of SRC. Actually, several reports about patients treated with angiotensin receptor blockers (ARBs) exist, but the general picture remains controversial: in 1997, an article reported the failure of losartan to control SRC in a patient [59], whereas another case report published in 2005 described a resolution of the crisis under treatment with ARB [60]. Most patients presenting SRC receive angiotensin-converting enzyme inhibitors (ACEi), a treatment which leads to a significant increase in the 5-year survival of SRC patients [61]. Nevertheless, a recent two-year prospective survey demonstrated that exposition to ACEi prior to the onset of SRC was associated with a higher risk of death, even when pre-existing hypertension backgrounds were taken into account. In contrast, ARB did not present these negative effects [4]. Moreover, analysis of the cohort from the European Scleroderma Trial and Research group (EUSTAR) showed that the cumulated incidence of SRC was higher for patients treated with ACEi, whereas ARBs had no influence [62]. Finally, another recent study revealed that ARB could delay the development of major vascular complications, such as SRC or pulmonary arterial hypertension in SSc patients, whereas use of ACEi was rather associated with an earlier onset of such complications [63]. These data underline the need for further large-scale, comparative studies to determine the effectiveness of ARB
in the treatment of SRC. Taking into account our results on SRC-IgG in the pathogenesis of SRC mediated by AT$_1$- and ET$_A$R, the use of ARBs appears more likely to be beneficial compared with ACEi, as mostly reported.

3.1. Study Limitations

We are aware that our study has limitations. Our IgG preparations stemmed from four patients with scleroderma renal crisis. However, as emphasized in a recent article, this complication has become increasingly rare over the years [64].

As a second limitation, we did not investigate the activation of NF-$\kappa$B and AP-1 transcription factors that have already been associated with AT$_1$R-Abs in acute kidney graft rejection. Nonetheless, the considerable effect of Ets-1 shRNA-mediated knockdown on proliferation and TF expression leads us to the conclusion that Ets-1 is a major player in the signaling axis that could lead to the endothelial phenotype of SRC.

Moreover, the spectrum methods is constantly evolving, and single-cell sequencing has noticeably changed the way studies are conducted. Applying this method to our experimental setting could hold the key to understand how SRC-IgG are affecting differentially specific blood vessels cell types.

Finally, IgG isolated from healthy controls do induce ERK1/2 activation and endothelial cell proliferation, but without involving AT$_1$R, ET$_A$R or Ets-1. Future studies should assess the exact particularities of patients and healthy autoantibodies.

3.2. Conclusions and Perspectives

Our results highlight a new mode of signaling and transcriptional regulation of TF by Ets-1, induced by autoantibodies against AT$_1$R and ET$_A$R. This adds a new layer of complexity to the concept, in which endothelial injury can be separated into two stages of response: first, a rapid, initial reaction; and second, a slower phenotypic response, the latter of which could trigger vascular remodeling [65]. Our studies further point to additional molecular mechanisms involving Ets-1 and TF. Hence, Ets-1 has been involved in dermal and renal fibrosis, and targeting this factor showed improvements in collagen dysregulation [13,66]. Concomitantly, TF has been associated with lung fibrosis, and therapeutic interventions with Dabigatran (anticoagulant) were conclusive [67]. Therapeutic strategies in SRC could be improved, associating specific targeting of new actors and known beneficial treatments, such as plasmapheresis [68].

4. Materials and Methods

4.1. Clinical Samples and IgG Isolation

Serum and plasma were obtained from four patients treated for angiotensin-converting enzyme I (ACEI) inhibitor-refractory SRC in our clinic between January 2006 and October 2010, after written informed consent and local ethics committee approval (EA1/013/705) had been received. SRC was defined by an otherwise unexplained rapid decline in renal function (increase in serum creatinine $\geq$50%) in patients with SSc. Diagnosis was confirmed by renal biopsy showing obliteratorive vasculopathy of arteries and arterioles in all cases (Table S4). All healthy and SRC individuals were tested for the presence of AT$_1$R and ET$_A$R antibodies using a sandwich ELISA (CellTrend GmbH, Luckenwalde, Germany), as described in detail in [69]. Only SRC patients showed high (above 10 U/mL) AT$_1$R- and ET$_A$R-IgG levels. All experiments were performed with four different individual IgG preparations isolated from plasma. IgG were isolated with HiTrap Protein G columns (GE Healthcare, Chicago, IL, USA). Briefly, plasma originating from the first plasmapheresis was aliquoted in 50 mL samples and frozen. Aliquots (50 mL) were thawed upon experimentation, mixed 1:1 with binding buffer (0.02 M Na$_2$HPO$_4$, pH 7.0) and filtered through a 0.45 $\mu$m filter to eliminate debris. The mix was then passed twice through a protein G column to bind IgG. Unspecific binding was removed by washing the column with binding buffer. IgG were eluted using a low-pH elution buffer (0.1 M Glycin-HCl,
pH 2.7), and harvested in fractions 4 to 8. The elution buffer was then neutralized with 1 M Tris, pH 9.0, and IgG were dialyzed against low-glucose DMEM overnight.

4.2. Cell Culture, Stimulation and Transfection

Human dermal microvascular endothelial cells (HMEC-1) were cultured in endothelial cell growth medium (PAA Laboratories GmbH, Pasching, Austria) with 5% (v/v) FBS. These cells reliably express AT₁R and ET₄R. For stimulation experiments, HMEC-1 were serum-starved for 24 h, then stimulated with SRC-IgG (1.5 mg/mL), ET-1 (0.1 µmol/L), AT-II (1 µmol/L). Pre-incubation with AT₁R or ET₄R inhibitors (Valsartan, Sigma Aldrich, Saint Louis, MI, USA and Sitaxentan, Pfizer, New York, NY, USA, respectively), MEK or Raf inhibitors (PD 184,352, Axon Medchem, Reston, VA, USA and GW5074, Sigma Aldrich, Saint Louis, MI, USA, respectively) were performed for two hours, whereas TF-blocking antibody (clone 5G9) was pre-incubated for 15 min. Western blots were performed as described previously [9]. Cells were rinsed twice with ice-cold 10 mM HEPES, 150 mM NaCl buffer, pH 7.5, before lysis in buffer containing 40 mM Tris/HCl, pH 8.0, 4 mM EDTA, 20% glycerol, 276 mM NaCl, 2% Triton X-100, 1 mM sodium vanadate, 2 mM sodium pyrophosphate, 10 mM sodium fluoride, 10 mM β-glycerophosphate, and complete protease inhibitor cocktail (Roche Diagnostics, Switzerland). After 20 min incubation on ice, the lysates were cleared by centrifugation at 14,000 rpm at 4 °C for 15 min. Protein concentrations were determined with Bio-Rad Protein Assay. Aliquots with a 40 µg total protein content were boiled in SDS-Laemmli buffer with 100 mM DTT for 5 min. Samples were loaded onto 10% Bis-Tris polyacrylamide gels and separated by electrophoresis. Proteins were transferred onto nitrocellulose membranes (GE Healthcare, Sweden), which were then blocked for one hour at room temperature with 5% non-fat milk (Applichem, Germany) and 1% bovine serum albumin (SERVA, Germany) in 0.1% Tween-Tris-buffered saline. Membranes were probed with phospho-ERK (Cell Signaling, Danvers, MA, USA), α-Tubulin (Sigma Aldrich, Saint Louis, MI, USA), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Santa Cruz, Dallas, TX, USA or Hytest Ltd., Turku, Finland), p38-Ets-1 (Invitrogen, Carlsbad, CA, USA), Ets-1 (Santa Cruz, Dallas, TX, USA), TF (American Diagnostica, Pfungstadt, Germany) antibodies. shRNA vectors provided by Santa Cruz were used to deliver scrambled or Ets-1 shRNA. Cells were transfected with TurboFect (Fermentas, Waltham, MA, USA), following the manufacturer’s instructions. After three hours, the medium was changed to starvation medium. On the next day, cells were stimulated.

4.3. Proliferation Assays

Proliferation was measured by Bromodeoxyuridine (BrdU) assay using either a kit (Roche Diagnostics, Switzerland) (Figure 3a,b) or immunofluorescence with anti-BrdU antibody from Cell Signaling (Danvers, MA, USA) or Alexa Fluor 488 mouse anti-BrdU antibody from BD Pharmingen (San Diego, CA, USA) (Figures 3d and 5d), as previously described [70]. Briefly, cells were seeded on glass coverslips coated with 0.2% porcine gelatin. After starvation overnight, cells were stimulated. One hour before the end of the stimulation, BrdU was diluted to a final concentration of 20 µM in the cell culture medium. Cells were then washed and fixed with paraformaldehyde 4% for 15 min. Permeabilization was performed with 0.5% Triton X100 for 3 min and cells were finally blocked overnight at 4 °C in BSA 1%. On the next day, the BrdU antibody was diluted 1/1000 in a PBS solution containing 1% BSA, 33 mM Tris-HCl pH 8.0, 0.33 mM MgCl₂ and 0.5 mM Mercaptoethanol and Dnase I 2 U/µL for one hour at 37 °C. After washing, secondary fluorescent antibody was incubated for 1 h 30 at 37 °C. DAPI was used to counterlabel nuclei. Cell counting was performed automatically using ImageJ version 1.48.

4.4. RNA Extraction and Quantitative RT-PCR

All primer sequences are provided in the Supplementary Material (Table S1). Total RNA was extracted from cultured cells, and quantitative reverse transcription (RT)-PCR was performed with an Applied Biosystems 7500 Fast Real-Time PCR system (Applied
Biosystem, Waltham, MA, USA) using Power SYBR Green PCR Master Mix. Relative amounts of gene transcript were calculated by the cycle threshold method and normalized for the endogenous reference (β2-microglobulin).

4.5. Reporter Constructs and Luciferase Assay

All primer sequences are provided in the Supplementary Material (Table S2). PCR products were cloned into a luciferase vector (pGL4.10, Promega, Madison, WI, USA). HMEC-1 were transfected with the TF reporter plasmid and co-transfected with the reference pRL-TK renilla plasmid. Luciferase activity was assessed with the dual-luciferase reporter assay system (Promega, Madison, WI, USA).

4.6. Nuclear Extracts and Electrophoretic Mobility Shift Assay (EMSA)

All primer sequences are provided in the Supplementary Material. Oligonucleotide probes were labeled using a Biotin 3’ End DNA Labeling Kit (Thermo Scientific, Darmstadt, Germany). Nuclear extracts were prepared using an NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo Scientific, Waltham, MA, USA). The probe for Ets-1 used in EMSA (5’-TGGGCAAAAGCATTCCGGAATTGCCC-3’) corresponds to the TF promoter region: -498 to -475 bp. The binding mixture contained 5 µg nuclear extract, 20 fmol labeled double-stranded probe, 1 µg poly-dI/dC, and 1X reaction buffer. Incubation was performed at room temperature for 30 min. Protein–DNA complexes were then analyzed by electrophoresis in 6% non-denaturing polyacrylamide gels and visualized using a LightShift Chemiluminescent EMSA Kit (Thermo Scientific, Darmstadt, Germany). In supershift experiments, nuclear extracts were incubated with Ets-1 antibody (Abcam, Cambridge, UK) before adding the biotin-labeled probe.

4.7. Chromatin Immunoprecipitation Assay (ChIP)

Formaldehyde cross-linking and ChIP were performed using the ChIP-IT High Sensitivity Kit (Active Motif, Carlsbad, CA, USA), following the manufacturer’s instructions. Briefly, after test exposure, HMEC-1 were fixed for 10 min with complete cell fixation solution containing 37% formaldehyde, and sonicated to generate 500–800 bp DNA fragments. Immunoprecipitation was performed with protein G agarose beads and 4 µg of Ets-1 antibody (Abcam, Cambridge, UK). Chromatin extracts were incubated with the antibodies at 4 °C overnight under mild shaking, and ChIP DNA was eluted according to the manufacturer’s instructions. Precipitated DNA was purified and amplified by PCR with specific TF primers positive or negative for the presence of the Ets-1 binding site. PCR amplifications were performed with the primers listed in the Supplementary Material (Table S3).

4.8. Chromogenic TF Activity Assay and Thrombin Secretion

TF activity was measured as described previously [71]. Stimulated or non-stimulated HMEC-1 were washed twice with ice-cold PBS. Cells were incubated for 15 min at 37 °C with 0.1 M n-octyl-β-D-glucopyranoside in HEPES buffer (200 µL total). TF activity was measured by adding 100 µL of the sample to a solution of 2 nM factor (F)VIIa, 150 nM FX, and 5 mM CaCl₂. Chromogenic FXa substrate (American Diagnostica, Pfungstadt, Germany) was added to each well (0.5 mM final). At intervals, samples were transferred to a microtiter plate containing EDTA buffer, which terminated the generation of FXa. OD increments were measured at 405 nm for 30 min using a kinetic ELISA plate reader (37 °C, Molecular Devices, San Jose, CA, USA). TF activity units were assessed by a standard curve. Thrombin secretion was measured with an AssayMax Human Thrombin ELISA Kit (Assaypro LLC, St Charles, MO, USA), as described previously [72].

4.9. Statistics

All statistical analyses were performed with GraphPad Prism v8.00 (GraphPad Software, San Diego, CA, USA). Statistical significance was assessed using Mann–Whitney U tests (* p < 0.05, ** p < 0.01, *** p < 0.001). Data are presented as the mean of independent
experiments with the amount of individual experiments provided in figure legends as "n = "; error bars depict the SEM calculated from these independent experiments. All experiments were performed with individual patient IgG and the results were only pooled for the graphical representation and statistical analysis.

**Supplementary Materials:** The following are available online https://www.mdpi.com/article/10.3390/ijms23010244/s1.

**Author Contributions:** G.R., R.C., A.P., H.H. and D.D. participated in the study design and data interpretation. R.C., A.P., N.Z., P.W., O.W., A.E., U.R., G.K., A.K. (Angela Kill), P.S. and M.H.-N. participated in in vitro experiments. B.H. gathered the clinical data. R.C. and A.P. performed the statistical analyses. D.D. and A.P. participated in the study coordination. A.P., P.S., G.K., J.K.-M., A.K. (Angelika Kusch), R.C. and G.R. participated in the manuscript preparation, with support from all other authors, who have read and approved the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** The study was supported by the Bundesministerium für Wirtschaft und Technologie (BMWI) via the Zentrales Innovationsprogram Mittelstand (ZIM), and the Bundesministerium für Bildung und Forschung (BMBF Fkz 01 GM 0310, C6, TP6) by sponsoring the German systemic sclerosis Network (DNSN). G.K., P.S. and R.C. are funded by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft) Project-ID 394046635—SFB 1365 (subproject A03 to G.K., R.C. and P.S.) and Project-ID 421152132—SFB 1423 (subprojects A01/A05/Z03 to P.S.). R.G. was funded through the excellence cluster Precision Medicine in Inflammation, project TH and CD1, the RTG 1727 “Modulation of Autoimmunity”, as well as the DFG project RI 1056 11-1/2.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Charité—Universitätsmedizin Berlin (EA1/013/705).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available as they may be used for further study in group.

**Acknowledgments:** The authors thank H. D. Orzechowski, who provided them with the HMEC cell line. The authors would like to dedicate this manuscript to Duska Dragun, who contributed extensively to the field of non-HLA antibodies.

**Conflicts of Interest:** H. Heidecke is employed by CellTrend GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**References**

1. Woodworth, T.G.; Suliman, Y.A.; Li, W.; Furst, D.E.; Clements, P. Scleroderma renal crisis and renal involvement in systemic sclerosis. *Nat. Rev. Nephrol. 2016, 12, 678–691. [CrossRef]*

2. Cannon, P.J.; Hassar, M.; Case, D.B.; Casarella, W.J.; Sommers, S.C.; LeRoy, E.C. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. *Medicine 1974, 53, 1–46. [CrossRef] [PubMed]*

3. Batal, I.; Domsic, R.T.; Medsger, T.A.; Bastacky, S. Scleroderma renal crisis: A pathology perspective. *Int. J. Rheumatol. 2010, 2010, 543704. [CrossRef]*

4. Hudson, M.; Baron, M.; Tatibouet, S.; Furst, D.E.; Khanna, D.; International Scleroderma Renal Crisis Study, I. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. *Semin. Arthritis Rheum. 2014, 43, 666–672. [CrossRef]*

5. Wallukat, G.; Homuth, V.; Fischer, T.; Lindschau, C.; Horstkamp, B.; Jupner, A.; Baur, E.; Nissen, E.; Vetter, K.; Neichel, D.; et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. *J. Clin. Investig. 1999, 103, 945–952. [CrossRef]*

6. Dragun, D.; Muller, D.N.; Brasen, J.H.; Fritsche, L.; Nieminen-Kelha, M.; Dechend, R.; Kintscher, U.; Rudolph, B.; Hoebeke, J.; Eckert, D.; et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. *N. Engl. J. Med. 2005, 352, 558–569. [CrossRef]*
7. Hiemann, N.E.; Meyer, R.; Wellnhofer, E.; Schoenemann, C.; Heidecke, H.; Lachmann, N.; Hetzer, R.; Dragun, D. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. *Transplantation* 2012, 94, 919–924. [CrossRef] [PubMed]

8. Giraud, M.; Foucher, Y.; Dufay, A.; Van Huyen, J.P.; Renaudin, K.; Moreau, A.; Philippe, A.; Hegner, B.; Dechend, R.; Heidecke, H.; et al. Pretransplant Sensitization Against Angiotensin II Type 1 Receptor Is a Risk Factor for Acute Rejection and Graft Loss. *Am. J. Transplant.* 2013, 13, 2567–2576. [CrossRef]

9. Riemekasten, G.; Philippe, A.; Nather, M.; Slowinski, T.; Muller, D.N.; Heidecke, H.; Matucci-Cerinic, M.; Czirjak, L.; Lukitsch, I.; Becker, M.; et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. *Ann. Rheum. Dis.* 2011, 70, 530–536. [CrossRef] [PubMed]

10. Dragun, D.; Catar, R.; Philippe, A. Non-HLA antibodies against endothelial targets bridging allo- and autoimmunity. *Kidney Int.* 2016, 89, 280–288. [CrossRef]

11. Rosenbaum, D.M.; Rasmussen, S.G.; Koblika, B.K. The structure and function of G-protein-coupled receptors. *Nature* 2009, 459, 356–363. [CrossRef] [PubMed]

12. Cabral-Marques, O.; Marques, A.; Gill, L.M.; De Vito, R.; Rademacher, J.; Gunther, J.; Lange, T.; Humrich, J.Y.; Klapa, S.; Schinke, S.; et al. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. *Nat. Commun.* 2018, 9, 5224. [CrossRef] [PubMed]

13. Feng, W.; Chumley, P.; Hu, P.; Rezoniew, G.; Jaimes, D.; Duckworth, M.W.; Xing, D.; Jaimes, E.A. Role of the transcription factor erythroid burst formation virus E26 oncogen homolog-1 (ETS-1) as mediator of the renal proinflammatory and profibrotic effects of angiotensin II. *Hypertension* 2012, 60, 1226–1233. [CrossRef]

14. Naito, S.; Shimizu, S.; Maeda, S.; Wang, J.; Paul, R.; Fagin, J.A. Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. *Am. J. Physiol.* 1998, 274, C472–C480. [CrossRef]

15. Peare, D.D.; Tian, R.X.; Nigro, J.; Jorgulescu, J.B.; Puzis, L.; Jaimes, E.A. Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. *Am. J. Physiol. Ren. Physiol.* 2008, 294, F1094–F1100. [CrossRef]

16. Zhan, Y.; Brown, C.; Maynard, E.; Anshelevich, A.; Ni, W.; Ho, I.C.; Oettgen, P. Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. *J. Clin. Investig.* 2005, 115, 2508–2516. [CrossRef] [PubMed]

17. Leng, R.X.; Pan, H.F.; Chen, G.M.; Feng, C.C.; Fan, Y.G.; Ye, D.Q.; Li, X.P. The dual nature of Ets-1: Focus to the pathogenesis of vascular inflammation and remodeling. *Autoimmun. Rev.* 2011, 10, 439–443. [CrossRef]

18. Wernert, N.; Justen, H.P.; Rothe, M.; Behrens, P.; Dreschers, S.; Neuhaus, T.; Florin, A.; Sachinidis, A.; Vetter, H.; Ko, Y. The Ets 1 transcription factor is upregulated during inflammatory angiogenesis in rheumatoid arthritis. *J. Mol. Med.* 2002, 80, 258–266. [CrossRef]

19. Oettgen, P. Regulation of vascular inflammation and remodeling by ETS factors. *Circ. Res.* 2006, 99, 1159–1166. [CrossRef]

20. Hert, D.; Rodewald, M.; Fraser, H.M.; Hack, G.; Konrad, R.; Kreienberg, R.; Wulff, C. Regulation of endothelial proliferation by ETS factors. *Hypertension* 2010, 56, 1226–1233. [CrossRef] [PubMed]

21. Arderiu, G.; Pena, E.; Aledo, R.; Badimon, L. Tissue factor-Akt signaling triggers microvessel formation. *J. Thromb. Haemost.* JTH 2012, 10, 1895–1905. [CrossRef] [PubMed]

22. Arderiu, G.; Pena, E.; Aledo, R.; Espinosa, S.; Badimon, L. Ets-1 transcription is required in tissue factor driven microvessel formation and stabilization. *Angiogenesis* 2015, 18, 657–669. [CrossRef] [PubMed]

23. Senchenkova, E.Y.; Russell, J.; Almeida-Paula, L.D.; Harding, J.W.; Granger, D.N. Angiotensin II-mediated microvascular thrombosis. *Hypertension* 2010, 56, 1089–1096. [CrossRef] [PubMed]

24. Monton, M.; Castilla, M.A.; Alvarez Arroyo, M.V.; Tan, D.; Gonzalez-Pacheco, F.R.; Lopez Farre, A.; Casado, S.; Caramelo, C. Effects of angiotensin II on endothelial cell growth: Role of AT-1 and AT-2 receptors. *J. Am. Soc. Nephrol.* JASN 1998, 9, 969–974. [CrossRef]

25. Wei, G.; Srinivasan, R.; Cantemir-Stone, C.Z.; Sharma, S.M.; Santhanam, R.; Weinstein, M.; Muthusamy, N.; Man, A.K.; Oshima, R.G.; Leone, G.; et al. Ets1 and Ets2 are required for endothelial cell survival during embryonic angiogenesis. *Blood* 2009, 114, 1123–1130. [CrossRef]

26. Arderiu, G.; Pena, E.; Aledo, R.; Badimon, L. Ets-1 transcription is required in tissue factor driven microvessel formation and stabilization. *Angiogenesis* 2015, 18, 657–669. [CrossRef] [PubMed]

27. Mousson, L.; Bussone, G.; Berezne, A.; Noel, L.H.; Guillevin, L. Scleroderma renal crisis. *J. Rheumatol.* 2014, 41, 1040–1048. [CrossRef]

28. Nguyen, B.; Assassi, S.; Arnett, F.C.; Mayes, M.D. Association of RNA polymerase III antibodies with scleroderma renal crisis. *J. Rheumatol.* 2010, 37, 1068. [CrossRef]

29. Penn, H.; Howie, A.J.; Kingdon, E.J.; Bunn, C.C.; Stratton, R.J.; Black, C.M.; Burns, A.; Denton, C.P. Scleroderma renal crisis: Patient characteristics and long-term outcomes. *QJM* 2007, 100, 485–494. [CrossRef]

30. Nihytanowa, S.I.; Denton, C.P. Autoantibodies as predictive tools in systemic sclerosis. *Nat. Rev. Rheumatol.* 2010, 6, 112–116. [CrossRef]

31. Iniesta Arandia, N.; Simeon-Aznar, C.P.; Guillen Del Castillo, A.; Colunga Arguelles, D.; Rubio-Rivas, M.; Trapiella Martinez, L.; Garcia Hernandez, F.J.; Saez Comet, L.; Egrubide Arberas, M.V.; Ortego-Centeno, N.; et al. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis. *Clin. Exp. Rheumatol.* 2017, 35 (Suppl. 106), 98–105.
32. Kill, A.; Tabeling, C.; Undeutsch, R.; Kuhl, A.A.; Gunther, J.; Radic, M.; Becker, M.O.; Heidecke, H.; Worm, M.; Witzenrath, M.; et al. Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. *Arthritis Res. Ther.* 2014, 16, R29. [CrossRef]

33. Zhu, N.; Gu, L.; Jia, J.; Wang, X.; Wang, L.; Yang, M.; Yuan, W. Endothelin-1 triggers human peritoneal mesothelial cells' proliferation via ERK1/2-Ets-1 signaling pathway and contributes to endothelial cell angiogenesis. *J. Cell Biochem.* 2019, 120, 3539–3546. [CrossRef]

34. Watanabe, D.; Takagi, H.; Suzuki, K.; Suzuki, I.; Oh, H.; Ohashi, H.; Kemmochi, S.; Uemura, A.; Ojima, T.; Suganami, E.; et al. Transcription factor Ets-1 mediates ischemia- and vascular endothelial growth factor-dependent retinal neovascularization. *Am. J. Pathol.* 2004, 164, 1827–1835. [CrossRef]

35. Feng, W.; Chumley, P.; Allon, M.; George, J.; Scott, D.W.; Patel, R.P.; Litovsky, S.; Jaimes, E.A. The transcription factor E26 transformation-specific sequence-1 mediates neo-intima formation in arteriovenous fistula. *J. Am. Soc. Nephrol.* JASN 2014, 25, 475–487. [CrossRef]

36. Mackman, N.; Tilley, R.E.; Key, N.S. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. *Arterioscler. Thromb. Vasc. Biol.* 2007, 27, 1687–1693. [CrossRef] [PubMed]

37. Steen, V.D. Scleroderma renal crisis. *Rheum. Dis. Clin. North Am.* 2003, 29, 315–333. [CrossRef]

38. Dixon, E.; Wu, H.; Muto, Y.; Wilson, P.; Humphreys, B. Spatially Resolved Transcriptomic Analysis of Acute Kidney Injury in a Female Murine Model. *J. Am. Soc. Nephrol.* JASN 2021, 32, 323–333. [CrossRef] [PubMed]

39. Inokuchi, S.; Kimura, K.; Sugaya, T.; Inokuchi, K.; Murakami, K.; Sakai, T. Hyperplastic vascular smooth muscle cells of the intrarenal arteries in angiotensin II type 1a receptor null mutant mice. *Kidney Int.* 2001, 60, 722–731. [CrossRef] [PubMed]

40. Wendel, M.; Knels, L.; Kummer, W.; Koch, T. Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. *J. Histochem. Cytochem.* 2006, 54, 1193–1203. [CrossRef] [PubMed]

41. Abraham, D.J.; Krieg, T.; Distler, J.; Distler, O. Overview of pathogenesis of systemic sclerosis. *Rheumatology* 2009, 48 (Suppl. 3), iii3–iii7. [CrossRef]

42. Cheng, J.; Gu, W.; Lan, T.; Deng, J.; Ni, Z.; Zhang, Z.; Hu, Y.; Sun, X.; Yang, Y.; Xu, Q. Single-cell RNA sequencing reveals cell type- and artery type-specific vascular remodelling in male spontaneously hypertensive rats. *Cardiovasc. Res.* 2021, 117, 1202–1216. [CrossRef] [PubMed]

43. Gaydosik, A.M.; Tabib, T.; Domsic, R.; Khanna, D.; Fusi, L.; Morse, C.M.; Lafyatis, R. Single-cell transcriptome analysis identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. *Ann. Rheum. Dis.* 2018, 77, 1117–1124. [CrossRef] [PubMed]

44. BMB Rep. 1990, 25, 17, 323–333. [CrossRef] [PubMed]

45. BMB Rep. 2019, 8, 1827–1835. [CrossRef] [PubMed]

46. Dong, F.; Zhang, X.; Wold, L.E.; Ren, Q.; Zhang, Z.; Ren, J. Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: Role of ETB receptor, NADPH oxidase and caveolin-1. *Br. J. Pharmacol.* 2005, 145, 323–333. [CrossRef]

47. Br. J. Pharmacol. 2014, 171, 10216–10227. [CrossRef] [PubMed]

48. Br. J. Pharmacol. 2015, 18, 10216–10227. [CrossRef] [PubMed]

49. Arterioscler. Thromb. Vasc. Biol. 1996, 16, 1687–1693. [CrossRef] [PubMed]

50. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 346–347. [CrossRef] [PubMed]

51. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 1193–1203. [CrossRef] [PubMed]

52. Arterioscler. Thromb. Vasc. Biol. 2019, 39, 1173–1181. [CrossRef] [PubMed]

53. Arthritis Res. Ther. 2014, 16, R29. [CrossRef] [PubMed]

54. Arthritis Res. Ther. 2016, 18, 111–122. [CrossRef] [PubMed]
57. Kambas, K.; Chrysanthopoulou, A.; Kourtzelis, I.; Skordala, M.; Mitroulis, I.; Rafail, S.; Vradelis, S.; Sigalas, I.; Wu, Y.Q.; Speletas, M.; et al. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. *J. Immunol.* 2011, 186, 6568–6575. [CrossRef]

58. Dechend, R.; Homuth, V.; Wallukat, G.; Kreuzer, J.; Park, J.K.; Theuer, J.; Juepner, A.; Gulba, D.C.; Mackman, N.; Haller, H.; et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. *Circulation* 2000, 101, 2382–2387. [CrossRef]

59. Caskey, F.J.; Thacker, E.J.; Johnston, P.A.; Barnes, J.N. Failure of losartan to control blood pressure in scleroderma renal crisis. *Lancet* 1997, 349, 620. [CrossRef]

60. Rajendran, P.R.; Molitor, J.A. Resolution of hypertensive encephalopathy and scleroderma renal crisis with an angiotensin receptor blocker. *J. Clin. Rheumatol.* 2005, 11, 205–208. [CrossRef]

61. Steen, V.D.; Medsger, T.A. Changes in causes of death in systemic sclerosis, 1972-2002. *Ann. Rheum. Dis.* 2007, 66, 940–944. [CrossRef]

62. Butikofer, L.; Varisco, P.A.; Distler, O.; Kowal-Bielecka, O.; Allanore, Y.; Riemekasten, G.; Villiger, P.M.; Adler, S.; Collaborators, E. ACE inhibitors in SSC patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. *Arthritis Res. Ther.* 2020, 22, 59. [CrossRef] [PubMed]

63. Bruni, C.; Cometi, L.; Gigante, A.; Rosato, E.; Matucci-Cerinic, M. Prediction and primary prevention of major vascular complications in systemic sclerosis. *Eur. J. Intern. Med.* 2021, 87, 51–58. [CrossRef]

64. Moinzadeh, P.; Kuhr, K.; Siegert, E.; Blank, N.; Sunderkoetter, C.; Henes, J.; Krusche, M.; Schmalzing, M.; Worm, M.; Schmeiser, T.; et al. Scleroderma Renal Crisis: Risk Factors for an Increasingly Rare Organ Complication. *J. Rheumatol.* 2020, 47, 241–248. [CrossRef]

65. Abraham, D.; Distler, O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. *Arthritis Res. Ther.* 2007, 9 (Suppl. 2), S2. [CrossRef]

66. Yang, Y.; Kim, H.J.; Woo, K.J.; Cho, D.; Bang, S.I. Lipo-PGE1 suppresses collagen production in human dermal fibroblasts via the ERK/Ets-1 signaling pathway. *PLoS ONE* 2017, 12, e0179614. [CrossRef] [PubMed]

67. Bogatkevich, G.S.; Ludwicka-Bradley, A.; Silver, R.M. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. *Arthritis Rheum.* 2009, 60, 3455–3464. [CrossRef]

68. Zanatta, E.; Polito, P.; Favaro, M.; Larosa, M.; Marson, P.; Cozzi, F.; Doria, A. Therapy of scleroderma renal crisis: State of the art. *Autoimmun. Rev.* 2018, 17, 882–889. [CrossRef] [PubMed]

69. Dragun, D. The detection of antibodies to the Angiotensin II-type 1 receptor in transplantation. *Methods Mol. Biol.* 2013, 1034, 331–333. [CrossRef] [PubMed]

70. Kusch, A.; Tkachuk, S.; Tkachuk, N.; Patecki, M.; Park, J.K.; Dietz, R.; Haller, H.; Dumler, I. The tight junction protein ZO-2 mediates proliferation of vascular smooth muscle cells via regulation of Stat1. *Cardiovasc. Res.* 2009, 83, 115–122. [CrossRef] [PubMed]

71. Pepke, W.; Eisenreich, A.; Jaster, M.; Ayral, Y.; Bobbert, P.; Mayer, A.; Schultheiss, H.P.; Rauch, U. Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells. *Cardiovasc. Ther.* 2013, 31, 115–123. [CrossRef] [PubMed]

72. Breyn, J.; Juthier, F.; Corceaux, D.; Marechaux, S.; Zawadzki, C.; Jeanpierre, E.; Ung, A.; Ennezat, P.V.; Susen, S.; Van Belle, E.; et al. Atherosclerotic-like process in aortic stenosis: Activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. *Atherosclerosis* 2010, 213, 369–376. [CrossRef] [PubMed]